Novo Nordisk A/S Common Stock (NVO)

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.

Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.

Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action.

It offers compelling weight-loss drugs -- and a compelling stock price, too.

It's not the end of the world for the drugmaker.

These two have been neglected by Wall Street too much.

As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the market. While specific daily performance metrics remain unreleased, today's trading likely saw the sector reacting to a

This pharma giant is entering the rapidly expanding market for weight loss drugs.

While Novo Nordisk has been victimized by broader market pressure, NVO stock has just flashed a reliable quant signal for bullish traders.

Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential.

Employer-sponsored health insurance costs rise for third year, with average family premiums at $27,000 in 2025. Drug costs and GLP-1s drive spending.

Congresswoman Marjorie Taylor Greene (R-Ga.) is among the most active traders in Congress. Here's a look at her latest trades disclosed, which comes with increased attention on Congress Trades from retail traders.

Copenhagen, Denmark – October 22, 2025 – Novo Nordisk (NYSE: NVO) shares experienced a notable decline this week following the announcement of a comprehensive board overhaul, a decisive move orchestrated by its top investor, the non-profit Novo Nordisk Foundation. The shake-up, which will see seven independent board members, including the chairman, step

The rapid growth rates of recent years aren't guaranteed to continue.

Don't try to catch a falling surgical knife.

The tides continue to change in Eli Lilly's favor in the GLP-1 space.

That's plenty of time for these drugmakers to move past their challenges.

These companies are jockeying for position in a potential $150 billion market opportunity.